<?xml version="1.0" encoding="UTF-8"?>
<p>Infections by protozoan parasites remain to be among the most devastating causes of mortality in the tropics. The trypanosomatids are a large family of flagellated protozoa, some of which cause neglected tropical diseases of high public health relevance and socio-economic impact (
 <xref rid="B91" ref-type="bibr">WHO, n.d.</xref>; 
 <xref rid="B26" ref-type="bibr">Filardy et al., 2018</xref>). These are 
 <italic>Trypanosoma cruzi</italic> (Chagas’ disease), 
 <italic>T. brucei gambiense</italic>, and 
 <italic>T. b. rhodesiense</italic> (human African trypanosomiasis or sleeping sickness), and 
 <italic>Leishmania</italic> spp. (different kinds of leishmaniasis) (
 <xref rid="B81" ref-type="bibr">Stuart et al., 2008</xref>). The apicomplexan parasite 
 <italic>Plasmodium falciparum</italic> is the causative agent of malaria tropica, the most dangerous form of malaria, which—despite the successes by various international bodies and philanthropic organizations—still claims an annual death toll of 435,000 (
 <xref rid="B89" ref-type="bibr">World Health Organisation, 2018</xref>). These diseases disproportionally affect the poor and vulnerable populations (
 <xref rid="B92" ref-type="bibr">WHO Expert Committee on Malaria: Twentieth Report, n.d.</xref>), calling for action to improve global well-being. A key element of the fight against protozoan neglected tropical diseases and malaria is the discovery of novel chemotherapeutic agents.
</p>
